LBPMedicine(SH:688393)2024-04-29 07:41Financial Performance - The company's operating revenue for Q1 2024 was ¥101,468,637.22, representing an increase of 11.82% compared to the same period last year[5] - The net profit attributable to shareholders was ¥7,989,313.63, reflecting a growth of 2.17% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥4,800,071.33, which is a significant increase of 78.59% compared to the previous year[5] - Basic earnings per share for the quarter were ¥0.09, up by 12.50% from the same period last year[6] - The company reported a net profit margin improvement, with net profit for Q1 2024 expected to reflect the growth in revenue and controlled costs[18] - In Q1 2024, the company reported a net profit of CNY 3,781,976.65, a significant increase compared to a net loss of CNY 166,119.75 in Q1 2023[19] - The total profit before tax was CNY 3,644,696.08, compared to CNY 701,953.85 in Q1 2023, reflecting improved operational efficiency[19] Research and Development - Total R&D investment amounted to ¥11,225,688.79, a decrease of 21.30% year-on-year, with R&D expenses accounting for 11.06% of operating revenue, down by 4.66 percentage points[6] - Research and development expenses decreased to CNY 8,740,663.97 from CNY 12,842,534.61 year-over-year, indicating a focus on cost management[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥24,475,755.67, indicating a significant cash outflow[5] - The company experienced a net cash outflow from operating activities of CNY 24,475,755.67, worsening from a net outflow of CNY 17,959,253.73 in Q1 2023[23] - Investment activities generated a net cash inflow of CNY 25,539,718.26, a turnaround from a net outflow of CNY 1,485,469.38 in the previous year[23] - The company’s cash and cash equivalents at the end of Q1 2024 were CNY 48,301,247.77, down from CNY 69,908,514.29 at the end of Q1 2023, indicating liquidity challenges[24] Assets and Liabilities - The company's total assets at the end of the quarter were ¥1,360,361,984.77, a decrease of 2.83% from the end of the previous year[6] - Cash and cash equivalents decreased to CNY 48,309,247.77 as of March 31, 2024, down from CNY 67,682,310.26 at the end of 2023, representing a decline of 28.7%[14] - Accounts receivable increased to CNY 240,636,187.42 as of March 31, 2024, compared to CNY 235,547,368.05 at the end of 2023, indicating a growth of 2.4%[15] - Inventory rose to CNY 83,386,438.52 as of March 31, 2024, compared to CNY 74,972,461.19 at the end of 2023, marking an increase of 11.2%[15] - Total assets decreased to CNY 1,360,361,984.77 as of March 31, 2024, down from CNY 1,399,930,972.74 at the end of 2023, a reduction of 2.8%[16] - Total liabilities decreased to CNY 116,599,959.59 as of March 31, 2024, compared to CNY 161,626,457.80 at the end of 2023, reflecting a significant decline of 28.0%[17] - The company's equity attributable to shareholders increased to CNY 1,273,276,162.13 as of March 31, 2024, up from CNY 1,263,611,314.91 at the end of 2023, a growth of 0.8%[17] - Deferred tax assets increased to CNY 30,358,519.60 as of March 31, 2024, compared to CNY 27,610,567.87 at the end of 2023, indicating a rise of 10.0%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,209[10] - The largest shareholder, Cai Xiangting, holds 21.18% of the shares, totaling 19,817,000 shares[11] Revenue and Costs - Total revenue for Q1 2024 reached CNY 101,468,637.22, an increase of 11.9% compared to CNY 90,744,669.29 in Q1 2023[18] - Total operating costs for Q1 2024 were CNY 100,768,978.49, up from CNY 95,787,160.28 in Q1 2023, reflecting a year-over-year increase of 5.2%[18] - The total revenue from operating activities was CNY 105,904,561.62, slightly up from CNY 105,121,133.68 in the same period last year[23] - The company reported a significant increase in financial income, with interest income rising to CNY 2,801,223.71 from CNY 2,421,531.93 in the previous year[19]